Each film coated tablet contains Pazopanib 200 mg as Pazopanib HCl INN.
Pazonib-200 is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Pazonib-200 is indicated for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Each film coated tablet contains Pazopanib 200 mg as Pazopanib HCl INN.
Pazonib-200 is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Pazonib-200 is indicated for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.